by Jose Leal, 5th December 2025 Where should we build the next stage of our work? This question has been driving my thinking about the Gulf for the past year. As Ophiomics moves from clinical validation… Precision Diagnostics in Saudi Arabia? The beauty of Scale
Why Qatar can – and must – claim the diagnostics translation space before regional competitors occupy it By José Pereira Leal, PhD Published on Linkedin on Dec 4th, 2025. Over the past year, I’ve been… Qatar’s Precision Diagnostics Opportunity: From Research Excellence to Industry Leadership
Published on LinkedIn on Dec 1st, 2025 In the global race for medical innovation, market size matters, but market access matters more. Today, a medical device manufacturer targeting the Gulf Cooperation Council (GCC) faces a… The 60-Million+ Patient Passport: Why the GCC Needs a “Gulf CE Mark”
Published on Linkedin on November 8th, 2025 Reading Qatar’s latest precision medicine and national strategy reports as my flight approached Doha, I found myself genuinely impressed and, as a veteran of biomedical strategy, more than… Qatar’s Precision Medicine Leap: From Vision to Innovation Economy
Published on Linkedin on October 12, 2025 I just spent three intense days at BioSpain 2025 (https://www.asebio.com/en/news-events/news/biospain-2025-closes-record-attendance-and-passes-baton-bilbao-2026-host-city), participating in a most intense (!) partnering marathon, and also had the privilege of participating in two roundtables.… Reflecting on Barcelona’s Ecosystem: Twenty-Odd Years of Convergence
At 35, Sarah suffered a heart attack that a €30 genetic test could have prevented. Her story isn’t unusual, it’s a mirror of how health systems worldwide confuse “standard care” with equity. Sarah, a 34-year-old… Precision Medicine Isn’t Elitist: It’s the Only Equitable Option
Published on Linkedin on August 3rd, 2025 While everyone chases longevity drugs, the real fountain of youth sits in your liver In the ever-expanding dialogue around longevity in a medical setting, we hear a lot… The Liver – Longevity Connection: Why Precision Liver Medicine Deserves a Seat at the Longevity Table
published on Linkedin on 20 July 2025. Every week, my LinkedIn feed is filled with billion-dollar AI alliances, breakthrough biomarker announcements, and government blueprints for “future healthcare.” Locally and globally, the numbers are extraordinary: the… If Precision Medicine Is the Future, Why Are We Neglecting Its Foundation?
Published on linkedin on June 17th 1. Not enough evidence! When we first embarked on developing Hepatopredict, our idea was very clear: create a biomarker-based test that could reliably inform clinical decisions about liver transplantation… From Promising to Proven: Lessons from the Validation Trenches of Biomarker Development
This reflection was heavily reliant on sourcing information and testing arguments with my favourite AI agent: Perplexity.AI. The ideas, interpretations, and conclusions are mine. The estimates on impact (e.g., life-years gained, cost savings) are approximations… Turning Precision Medicine from Ambition to Impact: Reflecting on a Liver Health Vertical in the UAE